HX111 for advanced solid tumors and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, HX111, in people with advanced solid tumors (like sarcomas, head and neck, cervical, or breast cancer) or certain lymphomas that have not responded to standard treatments. The goal is to see if HX111 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have an advanced solid tumor (such as sarcoma, head and neck, cervical, or breast cancer) or a specific type of lymphoma (like T-cell lymphoma or NK/T-cell lymphoma) that has not responded to standard therapy or for which no standard therapy exists.
- You can perform daily activities with little to no help (ECOG performance status 0-1).
- Your tumor or lymphoma can be measured on scans (at least one lesion that is 15 mm for lymph nodes or 10 mm elsewhere).
- Your blood, liver, kidney, and heart function are within acceptable limits (no severe organ problems).
- You have not had another cancer in the last 2 years (except for certain cured skin or bladder cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HX044 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and helps shrink tumors.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
This Phase 1 trial tests HLX51, a new anti-cancer medicine, to see if it is safe and tolerable in people with advanced solid tumors or lymphoma. It also studies how the body absorbs and processes the drug, and it may help if standard treatments didn’t work or aren’t possible.
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
Hear when a new Solid Tumor and Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.